{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:05:54Z","timestamp":1792191954132,"version":"4.4.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.jacc.2019.07.056","type":"journal-article","created":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T15:59:14Z","timestamp":1569254354000},"page":"1667-1678","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":259,"title":["Cardiovascular Toxicities Associated\u00a0With Ibrutinib"],"prefix":"10.1016","volume":"74","author":[{"given":"Joe-Elie","family":"Salem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Manouchehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Bretagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Lebrun-Vignes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Groarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishitha M.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Funck-Brentano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan M.","family":"Roden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javid J.","family":"Moslehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2019.07.056_bib1","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy","volume":"130","author":"Miklos","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2019.07.056_bib2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.07.056_bib3","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.07.056_bib4","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.07.056_bib5","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstrom's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.07.056_bib7","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","volume":"102","author":"Brown","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.jacc.2019.07.056_bib8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/leu.2017.175","article-title":"Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL\/SLL","volume":"32","author":"Brown","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jacc.2019.07.056_bib9","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/blood-2016-05-712828","article-title":"The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis","volume":"128","author":"Leong","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2019.07.056_bib10","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2018.06.002","article-title":"Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies","volume":"72","author":"Guha","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.07.056_bib11","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","article-title":"Ventricular arrhythmias and sudden death in patients taking ibrutinib","volume":"129","author":"Lampson","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2019.07.056_bib12","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.07.056_bib13","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jacc.2019.07.056_bib14","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"VigiBase, the WHO global ICSR database system: basic facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Drug Information Journal"},{"key":"10.1016\/j.jacc.2019.07.056_bib15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jaci.2018.09.001","article-title":"Characterizing drug-induced capillary leak syndromes using the World Health Organization VigiBase","volume":"143","author":"Mertz","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jacc.2019.07.056_bib16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A\u00a0Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2019.07.056_bib17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0962280211403604","article-title":"Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery","volume":"22","author":"Noren","year":"2013","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.jacc.2019.07.056_bib18","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1093\/eurheartj\/ehi092","article-title":"Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death","volume":"26","author":"De Bruin","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.07.056_bib19","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jacc.2019.07.056_bib20","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1136\/heartjnl-2017-312934","article-title":"Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors","volume":"104","author":"Grouthier","year":"2018","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2019.07.056_bib21","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1001\/jamacardio.2018.2251","article-title":"Association of oral contraceptives with drug-induced QT interval prolongation in healthy nonmenopausal women","volume":"3","author":"Salem","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2019.07.056_bib22","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.119.040162","article-title":"Androgenic\u00a0effects on ventricular repolarization: a\u00a0translational study from the International Pharmacovigilance Database to iPSC-Cardiomyocytes","author":"Salem","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.07.056_bib23","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3324\/haematol.2015.126672","article-title":"Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"100","author":"Lipsky","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.jacc.2019.07.056_bib24","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1182\/blood-2017-09-808808","article-title":"Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation in humans","volume":"131","author":"Busygina","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2019.07.056_bib25","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/jth.13651","article-title":"Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies","volume":"15","author":"Shatzel","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacc.2019.07.056_bib26","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s00280-017-3471-x","article-title":"Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study","volume":"80","author":"de Jong","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jacc.2019.07.056_bib27","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.clml.2018.06.016","article-title":"Safety analysis of four randomized controlled studies of ibrutinib in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma or mantle cell lymphoma","volume":"18","author":"O'Brien","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jacc.2019.07.056_bib28","first-page":"1491","article-title":"Ibrutinib-associated atrial fibrillation","volume":"4","author":"Ganatra","year":"2018","journal-title":"J\u00a0Am Coll Cardiol EP"},{"key":"10.1016\/j.jacc.2019.07.056_bib29","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/bloodadvances.2017009720","article-title":"Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib","volume":"1","author":"Wiczer","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jacc.2019.07.056_bib30","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/bjh.14324","article-title":"Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study","volume":"175","author":"Thompson","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jacc.2019.07.056_bib31","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.phrs.2017.06.004","article-title":"Effectiveness of heart rate control on hemodynamics in critically ill patients with atrial tachyarrhythmias managed by amiodarone","volume":"122","author":"Salem","year":"2017","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jacc.2019.07.056_bib32","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2353\/ajpath.2009.090126","article-title":"Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation","volume":"175","author":"Pretorius","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jacc.2019.07.056_bib33","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"McMullen","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2019.07.056_bib34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pharmthera.2018.04.009","article-title":"Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms","volume":"189","author":"Alexandre","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jacc.2019.07.056_bib35","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/fcp.12091","article-title":"Pharmacology and mechanisms of action of new oral anticoagulants","volume":"29","author":"Salem","year":"2015","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.jacc.2019.07.056_bib36","first-page":"7304021","article-title":"Profound sinoatrial arrest associated with ibrutinib","volume":"2017","author":"Mathur","year":"2017","journal-title":"Case Rep Oncol Med"},{"key":"10.1016\/j.jacc.2019.07.056_bib37","first-page":"8","article-title":"Electrophysiological mechanisms of long and short QT syndromes","volume":"14","author":"Tse","year":"2017","journal-title":"Int J Cardiol Heart Vasc"},{"key":"10.1016\/j.jacc.2019.07.056_bib38","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1001\/jama.2009.888","article-title":"Long-term outcomes in individuals with prolonged PR interval or first-degree atrioventricular block","volume":"301","author":"Cheng","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2019.07.056_bib39","article-title":"Prolonged PR interval predicts clinical recurrence of atrial fibrillation after catheter ablation","volume":"3","author":"Park","year":"2014","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2019.07.056_bib40","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGENETICS.116.001482","article-title":"Investigating the genetic architecture of the PR interval using clinical phenotypes","volume":"10","author":"Mosley","year":"2017","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.jacc.2019.07.056_bib41","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1080\/10428194.2018.1457149","article-title":"Ibrutinib-associated ventricular arrhythmia in the FDA Adverse Event Reporting System","volume":"59","author":"Cheng","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jacc.2019.07.056_bib42","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/j.jacc.2006.02.009","article-title":"Short QT interval and atrial fibrillation in patients without structural heart disease","volume":"47","author":"Poglajen","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.07.056_bib43","first-page":"847","article-title":"Ibrutinib, an approved tyrosine kinase inhibitor as a potential cause of recurrent polymorphic ventricular tachycardia","volume":"2","author":"Tomcsanyi","year":"2016","journal-title":"J\u00a0Am Coll Cardiol EP"},{"key":"10.1016\/j.jacc.2019.07.056_bib44","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.jemermed.2016.10.019","article-title":"A\u00a0perfect storm: tyrosine kinase inhibitor-associated polymorphic ventricular tachycardia","volume":"52","author":"Beyer","year":"2017","journal-title":"J\u00a0Emerg Med"},{"key":"10.1016\/j.jacc.2019.07.056_bib45","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1161\/01.CIR.89.1.206","article-title":"Short-coupled variant of torsade de pointes. A new electrocardiographic entity in the spectrum of idiopathic ventricular tachyarrhythmias","volume":"89","author":"Leenhardt","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.07.056_bib46","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.hrthm.2016.10.015","article-title":"A\u00a0type 2 ryanodine receptor variant associated with reduced Ca(2+) release and short-coupled torsades de pointes ventricular arrhythmia","volume":"14","author":"Fujii","year":"2017","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2019.07.056_bib47","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.yjmcc.2017.04.005","article-title":"Beta-adrenergic induced SR Ca(2+) leak is mediated by an Epac-NOS pathway","volume":"108","author":"Pereira","year":"2017","journal-title":"J\u00a0Mol Cell Cardiol"},{"key":"10.1016\/j.jacc.2019.07.056_bib48","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1210\/jc.2016-1877","article-title":"Complex influence of gonadotropins and sex steroid hormones on QT interval duration","volume":"101","author":"Abehsira","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2019.07.056_bib49","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1161\/CIRCULATIONAHA.118.034282","article-title":"Hypogonadism as a reversible cause of torsades de pointes in men","volume":"138","author":"Salem","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.07.056_bib50","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.pharmthera.2016.07.005","article-title":"Influence of steroid hormones on ventricular repolarization","volume":"167","author":"Salem","year":"2016","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jacc.2019.07.056_bib51","first-page":"433","article-title":"Concomitant treatment with ibrutinib and amiodarone causing reversible heart failure syndrome","volume":"18","author":"Wasserstrum","year":"2016","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.jacc.2019.07.056_bib52","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/ccr3.719","article-title":"A\u00a0case of new-onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma","volume":"4","author":"Wallace","year":"2016","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.jacc.2019.07.056_bib53","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1158\/1535-7163.MCT-15-0923","article-title":"Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell\u00a0Growth","volume":"15","author":"Chen","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jacc.2019.07.056_bib54","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.07.056_bib55","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.2174\/138161211796390976","article-title":"Phosphoinositide-3 kinase signaling in cardiac hypertrophy and heart failure","volume":"17","author":"Aoyagi","year":"2011","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jacc.2019.07.056_bib56","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/MBC.0000000000000749","article-title":"Ibrutinib-related bleeding: pathogenesis, clinical implications and management","volume":"29","author":"Aguilar","year":"2018","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jacc.2019.07.056_bib57","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies","volume":"375","author":"Moslehi","year":"2016","journal-title":"N\u00a0Engl J Med"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109719361558?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109719361558?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:24:42Z","timestamp":1760016282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109719361558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":56,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0735109719361558"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2019.07.056","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Toxicities Associated\u00a0With Ibrutinib","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2019.07.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}